… A similar range of HSUV values was seen among patients being treated for advanced
NSCLC or mNSCLC when the treatment line was unspecified (0.53–0.77) [42, 47, 52, 53]. Only …

… In comparison with normative data (table II), NSCLC was found to decrease the … utility of
0.78,[18] our results indicate a mean relative reduction in utility of 26% in patients with NSCLC. …

… Health state preference scores or utilities measure the strength of … The utilities in our model
were derived from a recent … , a subgroup analysis comparing patients with similar levels of …

… and quality of life for NSCLC patients via utility values is an … in utility values for different
non-small cell lung cancer (NSCLC) … use caution when comparing utility estimates generated with …

… However, researches on CAM use by cancer patients are scarce in Ethiopia. This study … as
comparing quality of life (QoL) in CAM users and non-users among cancer patients receiving …

… -utility analysis was to assess the incremental cost-effectiveness ratio (ICER) of either the
gemcitabine or erlotinib strategy compared to observation, for all NSCLC patients … comparisons …

… 2011–2015 for comparison. An experienced … patients with lung cancer in Taiwan have
NSCLC, we further explored participants with recurrent or newly diagnosed stage IIIB to IV NSCLC…

… utility values in patients with advanced NSCLC were studied. HRQOL, as measured by the
EQ-5D domains, and utility were lower in patients … Comparing of the utility in PF patients on …

… In particular, we were interested in comparing the HUSs of patients with driver mutations on
targeted treatment versus patients with WT NSCLC and SCLC treated with chemotherapy, or …

… showed that the utility of patients receiving gefitinib in DFS state was the most dominant
influence index, followed by the utility of DFS patients receiving chemotherapy and utility of PD …